Acrobiosystems Co.,Ltd. (SHE:301080)
50.08
-0.62 (-1.22%)
At close: Feb 13, 2026
Acrobiosystems Revenue
Acrobiosystems had revenue of 225.62M CNY in the quarter ending September 30, 2025, with 37.50% growth. This brings the company's revenue in the last twelve months to 794.52M, up 33.63% year-over-year. In the year 2024, Acrobiosystems had annual revenue of 645.02M with 18.65% growth.
Revenue (ttm)
794.52M
Revenue Growth
+33.63%
P/S Ratio
10.51
Revenue / Employee
914.29K
Employees
869
Market Cap
8.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 645.02M | 101.37M | 18.65% |
| Dec 31, 2023 | 543.65M | 69.22M | 14.59% |
| Jan 1, 2023 | 474.43M | 89.44M | 23.23% |
| Jan 1, 2022 | 384.99M | 138.67M | 56.30% |
| Dec 31, 2020 | 246.32M | 143.03M | 138.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.83B |
| Suzhou Fengbei Biotech Stock | 2.81B |
| Nanjing Vazyme Biotech | 1.34B |
| Chengdu Kanghua Biological Products | 1.21B |
| Shanghai Medicilon | 1.08B |
| Wuhan Keqian Biology Co.,Ltd | 1.01B |
| Jiangxi Fushine Pharmaceutical | 970.32M |
| R&G PharmaStudies | 789.45M |